Dxd (Exatecan derivative for ADC) is a potent DNA topoisomerase I inhibitor, with an IC 50 of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a). Dxd is cytotoxic to …

2022年6月5日 · The drug, trastuzumab deruxtecan (T-DXd), was approved based on a clinical trial led by Memorial Sloan Kettering Cancer Center (MSK) breast medical oncologist Shanu …

Trastuzumab deruxtecan, sold under the brand name Enhertu, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to …

On January 17, 2025, the Food and Drug Administration approved datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.), a Trop-2-directed antibody and topoisomerase inhibitor …

2024年5月3日 · On August 5, the agency gave an accelerated approval for trastuzumab deruxtecan —often called T-DXd—to treat anyone with any advanced solid cancer if their …

2022年7月5日 · Trastuzumab deruxtecan, also known as T-DXd, “is the first HER2- targeted therapy shown to provide clinically meaningful improvement in progression-free and overall …

2023年11月3日 · Trastuzumab deruxtecan (DS-8201, T-DXd, Enhertu®) is composed of the already approved HER2-targeting antibody trastuzumab, attached to 8 DXd payloads through …

Trastuzumab deruxtecan is a humanized anti-HER2 IgG1 antibody, targeting cancer cause by mutation of the HER2 gene. In addition, the small molecule portion of this drug, deruxtecan …

Trastuzumab deruxtecan (T-DXd) is a novel antibody–drug conjugate with a tetrapeptide linker, which delivers a topoisomerase I inhibitor with a drug-to-antibody ratio of 7~8. The potency of …

2024年4月15日 · The drug to antibody ratio (DAR) of Dato-DXd is 4:1, and the specific features of the linker makes Dato-DXd highly stable in circulation. Specifically, the payload of Dato-DXd is …